Progyny, Inc., a benefits management company, specializes in fertility benefits and family development solutions for employers in the United States. The company is headquartered in New York, New York.
| Revenue (TTM) | $1.34B |
| Gross Profit (TTM) | $332.99M |
| EBITDA | $140.11M |
| Operating Margin | 10.30% |
| Return on Equity | 18.70% |
| Return on Assets | 11.30% |
| Revenue/Share (TTM) | $16.71 |
| Book Value | $5.54 |
| Price-to-Book | 6.14 |
| Price-to-Sales (TTM) | 1.93 |
| EV/Revenue | 1.77 |
| EV/EBITDA | 17.90 |
| Quarterly Earnings Growth (YoY) | 113.30% |
| Quarterly Revenue Growth (YoY) | 8.90% |
| Shares Outstanding | $74.11M |
| Float | $68.39M |
| % Insiders | 2.04% |
| % Institutions | 111.19% |
Volatility is currently expanding
Progyny NASDAQ: PGNY raised the midpoint of its full-year 2026 guidance after reporting record third-quarter revenue and profitability and securing a record 1.3 million new covered lives during its latest selling season.
Reports Record Third Quarter Results for Revenue, Gross Profit, Adjusted EBITDA and Net IncomeSelling Season Yields Record 1.3 Million New Covered Lives with Another Year of Near 100% Retention Raises Midpoint of Full Year Guidance Ranges NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY) (“Progyny” or the “Company”), a global leader in women's health and family building solutions, today announced its financial results for the three-month period ended September 30, 2026 (“the third quarter of 2026”), as compared to the three-month period ended September 30, 2025 (“the third quarter of 2025” or “the prior year period”). “We're exceptionally pleased with the results of our most recent selling season, where our momentum extended even into its latest stages, yielding 1.3 million new covered lives, our most ever in a single season, and over 85 new clients,” said Pete Anevski, Chief Executive Officer of Progyny.
NEW YORK, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, today announced findings from a new clinical outcomes study showing significant improvements in menopause symptoms among members receiving care through its Menopause and Midlife program. The research found that more than 70% of members in the study experienced improvement in their menopause symptoms, with the greatest gains observed among those who received both personalized coaching and care from menopause-trained providers.
NEW YORK, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, will report its financial results for the quarterly period ended September 30, 2026, after the close of the market on Wednesday, November 4, 2026.
NEW YORK, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, announced today that it will present new research evaluating real-world outcomes from its Menopause and Midlife program and exhibit at The Menopause Society 2026 Annual Meeting in San Diego, October 20 – 24, 2026.
Progyny (PGNY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Investors interested in Medical Services stocks are likely familiar with Progyny (PGNY) and Charles River Laboratories (CRL). But which of these two companies is the best option for those looking for undervalued stocks?
Expecting 1.2 Million New Covered Lives from Commitments to Date and Anticipated Remaining Decisions Reflects How Employers are Increasingly Turning to Solutions with a Proven Track Record of Delivering Savings, Total Cost Management and ROI Progyny's Solutions Creating Compelling Opportunities for Employers to Stem Impacts from Broader Medical Cost Inflation Trend While Maintaining or Expanding Coverage of Services Impactful to their Workforce NEW YORK, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY) (“Progyny” or the “Company”), a global leader in women's health and family building solutions, today revealed key insights from the Company's current annual selling season, based on both commitments received to date and anticipated remaining decisions which are expected to contribute 1.2 million new covered lives from launches throughout the first half of 2027. Employers are now weighing how to best meet the complex needs of their workforce while simultaneously wrestling with the broader escalation in the overall medical cost trend.
Investors looking for stocks in the Medical Services sector might want to consider either Progyny (PGNY) or Charles River Laboratories (CRL). But which of these two stocks presents investors with the better value opportunity right now?
Progyny (PGNY) remains the US market leader in fertility benefits management, demonstrating robust growth, improving margins, and a compelling valuation despite recent volatility. PGNY's Q2 2026 results highlight 11% revenue growth ex-Amazon, margin expansion, and nearly 100% EPS growth guidance for 2026, supporting a continued buy rating. Secular tailwinds—rising infertility rates, delayed family formation, and underpenetrated employer markets—position PGNY for sustained double-digit growth and market share gains.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on PGNY and any ticker you trade — then tracks every position and per-strategy win rate.
